ESMO 2022 | Perioperative strategies in high-risk and oligometastatic renal cell and urothelial cancers

Enrique Grande, MD, PhD, MSc, MD Anderson Cancer Center Madrid, Madrid, Spain, discusses perioperative strategies in high-risk and oligometastatic renal cell and urothelial cancers, touching on neoadjuvant Phase III trials randomized trials in the cisplatin-eligible and ineligible urothelial cancer population, such as the IMmotion010 (NCT03024996), PROSPER (NCT03055013), and CheckMate 914 (NCT03138512). Dr Grande also highlights the results from KEYNOTE-564 (NCT03142334) which evaluated adjuvant pembrolizumab after nephrectomy in renal cell carcinoma. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.